JCI Impact Factor 2026: 13.6 | The Gold Standard for Translational Medicine

The Journal of Clinical Investigation's impact factor is 13.6 in 2024: down from 19.5 in 2021 but stabilizing as the COVID citation surge normalizes. At 15% acceptance, JCI is substantially more accessible than Nature Portfolio journals while holding rigorous translational standards. The filter is specific: papers need explicit bench-to-bedside bridging. Mouse-only mechanistic studies that don't connect to human disease rarely advance past triage.

What is JCI's impact factor?

JCI's current impact factor is 13.6 for the 2024 reporting year. The metric is useful, but the decision should be based on trend direction, acceptance dynamics, editorial behavior, and how your manuscript profile matches what editors actually advance.

Year-by-year impact factor trend (2017-2024)

Source: Clarivate Journal Citation Reports (JCR), 2025 edition.

Why the IF declined and where it's heading

JCI's drop from 19.5 (2021) to 13.6 (2024) follows the COVID normalization pattern seen across translational and clinical journals. JCI's pre-pandemic level was around 13-14, so the current 13.6 is slightly below historical levels but reflects ongoing normalization rather than any change in editorial standards.

What hasn't changed: JCI's reputation for rigorous peer review and meaningful feedback. Among translational journals in the 10-15 IF range, JCI consistently attracts the strongest reviewer pool, and the review quality shows : even rejection letters are notably more substantive than at comparable journals.

What JCI editors look for

JCI strongly favors studies that connect molecular mechanism to patient disease biology. Mouse only narratives are often declined unless human tissue, clinical cohorts, or convincing translational linkage is present. Editors want a clear bench to bedside arc, not only mechanistic elegance.

JCI editors require explicit bridging between mechanism and human disease. Mouse-only studies without human samples, patient-derived cells, or at minimum a strong clinical correlation rarely advance. The review criteria explicitly ask 'what is the clinical significance?' as a first-order question. This means papers that have strong mouse mechanistic data but minimal human relevance should look at Immunity, JEM, or Journal of Immunology first.

Here is the surprising operational detail most authors miss, JCI is known for unusually detailed reviewer feedback even on rejected papers, so many authors use the first JCI round as a high quality scientific stress test before targeting a second journal. This is why two manuscripts with similar technical quality can have very different outcomes at editorial triage.

What the 15% acceptance rate means in practice

With acceptance around 15%, JCI is selective but materially more accessible than top Nature journals. Papers that combine mechanistic depth, strong statistics, and at least one credible human anchor perform best. The sister journal JCI Insight provides a practical fallback with 20-25% acceptance for solid but slightly narrower studies.

At ~15% acceptance, JCI is substantially more accessible than Nature Portfolio journals (5%) while maintaining rigorous standards. The main filter is the bench-to-bedside requirement : papers that don't connect mechanism to human disease are consistently stopped. Once that bar is cleared, JCI's review process focuses on mechanistic rigor and dataset completeness.

Timeline: submission to decision

Desk rejections arrive in 5-7 business days. Peer review decisions typically come in 35-45 days. JCI reviewers are known for writing thorough, constructive feedback even on rejections : many authors specifically value JCI for this.

JCI Insight (IF ~6.1) is worth having as a deliberate strategy, not just a backup. Some teams deliberately publish a first paper in JCI Insight, build on reviewer feedback, then target JCI for a follow-up study. The sister journals share editorial standards and reviewer networks, so the progression is intentional.

What gets desk rejected at JCI

JCI rejects roughly 85% of submissions at triage. The editorial team is specific about what they're looking for, and understanding the failure modes can help you self-filter.

Common desk rejection triggers at JCI:

• Mouse-only mechanistic studies without human relevance. This is JCI's most consistent rejection pattern. Papers that present elegant mouse mechanism without human samples, patient-derived material, or an explicit clinical correlation are regularly declined. One well-powered human dataset changes the equation substantially.
• Weak clinical translation statement. Papers that bury the disease relevance in the discussion rather than leading with it at triage. JCI editors want to see the bench-to-bedside connection in the abstract, not just the methods.
• Mechanism without disease specificity. Papers about basic cell biology that aren't connected to a specific disease or clinical condition face harder triage. Even strong mechanistic work needs an explicit disease hook.
• Confirmatory studies without new mechanistic depth. Studies that replicate a known finding in a new cell type, animal model, or patient cohort without adding mechanistic insight are usually declined. JCI values mechanistic novelty, not just additional validation.
• Overpromised clinical relevance. The editorial team is experienced. Papers that assert clinical significance through speculation rather than data, or that overstate translational implications, are often caught and declined at triage.

How JCI compares to JEM and Nature Medicine

The JCI vs Journal of Experimental Medicine (JEM) comparison comes up often for immunology and disease biology work. JCI has a slight edge for translational work with direct human disease data. JEM has a slight edge for fundamental immunology and basic disease mechanisms. Both are rigorous and well-regarded : the practical choice usually comes down to how much human disease data you have and how explicitly clinical the paper's framing is.

Publication costs and open access

JCI is published by the American Society for Clinical Investigation (ASCI) and offers a hybrid open access model.

Standard publication (subscription track): No APC. Standard submission and publication with no author charges for qualifying manuscripts. JCI is one of the few high-impact journals in its tier that doesn't charge page fees.

Open access: Authors can pay $3,000 for immediate gold open access under a Creative Commons license. This satisfies most funder mandates.

JCI Insight (the sister open-access journal, IF ~6.1) charges an APC of approximately $2,500. JCI Insight is fully open access and doesn't have a subscription track.

The absence of standard page charges at JCI is notable : Cell Press journals charge $1,000-$1,500 even on accepted papers, and Nature Portfolio charges $11,690 for gold OA. JCI's cost structure is significantly more author-friendly, which is part of why it maintains strong submission volume despite a high bar.

When to submit to JCI

If your manuscript bridges mechanism and human disease with at least one convincing human data layer, submit to JCI before chasing higher IF brands that may desk reject on scope shorthand. This is not a journal to test incomplete narratives. Submit when the manuscript is already in target shape, not when you hope reviewer feedback will create the shape for you.

If you are aiming at this tier and want to reduce desk rejection risk, run a pre-submission diagnostic first: try the quick diagnostic.

FAQ

What is the JCI impact factor in 2024?

JCI impact factor is 13.6 in 2024.

What does JCI look for in submissions?

JCI looks for mechanistic rigor tied directly to human disease relevance, ideally with human data or clear translational grounding.

How does JCI compare to Journal of Experimental Medicine?

Both are selective and rigorous. JCI is often viewed as more explicitly translational with strong focus on bench to bedside narratives.

What is JCI Insight?

JCI Insight is the sister journal with a slightly lower selectivity bar and strong fit for solid translational studies.

Is JCI good for translational research?

Yes. It's one of the most respected venues for mechanistic studies that directly connect to human disease.

Sources and further reading

Impact factor data sourced from Clarivate Journal Citation Reports (released June 2025). For submission guidelines, see the JCI submission portal.

For full submission requirements, acceptance rates, and review timelines, see the JCI journal guide. For submission strategy and how to avoid desk rejection, see our guide on avoiding desk rejection.

The Bottom Line

JCI at 13.6 publishes mechanistic translational work at the highest level in the field. The bar is clear pathophysiological insight with clinical relevance , not just well-executed bench science. If your paper meets that standard, the IF makes JCI a strong choice. Run a pre-submission check to make sure the framing matches what reviewers will look for.

See also

• Nature Medicine Impact Factor 2026
• JCI Submission Guide
• NEJM Impact Factor 2026
• JCI Submission Guide: Process & Timeline